Research
Molecular
Non-alcoholic fatty liver disease (NAFLD) increases the risk of incident type 2 diabetes (T2D).
Practitioners should monitor T2D risk in patients with NAFLD.
StrongSupportsmedium confidence
NAFLD increases the risk of incident T2D.
Why this rating
The claim is based on epidemiological studies.
Source
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
Bertrand Cariou · Diabetes Obesity and Metabolism · 2022
DOI 10.1111/dom.14651
reviewCited 49×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Therapeutic strategies that promote significant and sustained weight loss (~10% of total body weight) are among the most efficient for treating NASH and T2D.Strong
- Insulin sensitizers such as PPARγ (pioglitazone) and pan-PPARs agonists (lanifibranor) have shown beneficial effects on both NASH and liver fibrosis.Strong
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →